Evaluating the effect of astaxanthin supplement on the levels of trace elements in patients with type 2 diabetes treated with metformin

Evaluation the effect of astaxanthin supplementation on the plasma and cellular levels of magnesium, zinc, copper and selenium in patients with type 2 diabetes treated by metformin

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190305042939N3

Enrollment

Registered

2022-11-10

Start date

2022-11-22

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: Astaxanthin supplement

For 8 weeks, they will receive one 10 mg astaxanthin soft gel tablet daily. Intervention 2: Control group: They will receive 1 placebo tablet containing starch daily for 8 weeks.

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetesTreated by metformin Age: 20-60 years

Exclusion criteria

Exclusion criteria: Patients with type 1 diabetes Pregnant women Women in lactation Taking any anti diabetic drug other than metformin Patients with other endocrine disorders Take any other antioxidant supplement

Design outcomes

Primary

Measure	Time frame
Cellular levels of magnesium. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.;Cellular levels of zinc. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.;Cellular levels of copper. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.;Cellular levels of selenium. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.	—

Measure

Time frame

Cellular levels of magnesium. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.;Cellular levels of zinc. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.;Cellular levels of copper. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.;Cellular levels of selenium. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.

—

Secondary

Measure	Time frame
Plasma levels of magnesium. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.;Plasma levels of Zinc. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.;Plasma levels of copper. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.;Plasma levels of selenium. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.	—

Measure

Time frame

Plasma levels of magnesium. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.;Plasma levels of Zinc. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.;Plasma levels of copper. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.;Plasma levels of selenium. Timepoint: Before and at the end of intervention. Method of measurement: Atomic absorption analysis.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hosein Araabi

Esfahan University of Medical Sciences

Mh.aarabi@pharm.mui.ac.ir+98 31 3792 7052

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026